AtriCure, Inc. (ATRC)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 41.44 |
| Open | 42.44 |
| Bid | 17.02 x 800 |
| Ask | 43.50 x 800 |
| Day's range | 42.28 - 43.10 |
| 52-week range | 38.64 - 89.18 |
| Volume | |
| Avg. volume | 254,716 |
| Market cap | 1.994B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | 39.52 |
| EPS (TTM) | 1.09 |
| Earnings date | 02 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 80.67 |
- Zacks
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
AtriCure Reports First Quarter 2022 Financial Results
MASON, Ohio, May 03, 2022--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results.
- Simply Wall St.
AtriCure (NASDAQ:ATRC) shareholders are still up 126% over 5 years despite pulling back 11% in the past week
It might be of some concern to shareholders to see the AtriCure, Inc. ( NASDAQ:ATRC ) share price down 21% in the last...
© 2022 Yahoo. All rights reserved.
